<?xml version='1.0' encoding='utf-8'?>
<document id="22570363"><sentence text="Translational evaluation of JNJ-18038683, a 5-hydroxytryptamine type 7 receptor antagonist, on rapid eye movement sleep and in major depressive disorder."><entity charOffset="44-63" id="DDI-PubMed.22570363.s1.e0" text="5-hydroxytryptamine" /></sentence><sentence text="In rodents 5-hydroxytryptamine type 7 (5-HT(7)) receptor blockade has been shown to be effective in models of depression and to increase the latency to rapid eye movement (REM) sleep and decrease REM duration"><entity charOffset="11-30" id="DDI-PubMed.22570363.s2.e0" text="5-hydroxytryptamine" /></sentence><sentence text=" In the clinic, the REM sleep reduction observed with many antidepressants may serve as a biomarker" /><sentence text=" We report here the preclinical and clinical evaluation of a 5-HT(7) receptor antagonist, (3-(4-chlorophenyl)-1,4,5,6,7,8-hexahydro-1-(phenylmethyl)pyrazolo[3,4-d]azepine 2-hydroxy-1,2,3-propanetricarboxylate) (JNJ-18038683)"><entity charOffset="90-208" id="DDI-PubMed.22570363.s4.e0" text="(3-(4-chlorophenyl)-1,4,5,6,7,8-hexahydro-1-(phenylmethyl)pyrazolo[3,4-d]azepine 2-hydroxy-1,2,3-propanetricarboxylate" /></sentence><sentence text=" In rodents, JNJ-18038683 increased the latency to REM sleep and decreased REM duration, and this effect was maintained after repeated administration for 7 days" /><sentence text=" The compound was effective in the mouse tail suspension test" /><sentence text=" JNJ-18038683 enhanced serotonin transmission, antidepressant-like behavior, and REM sleep suppression induced by citalopram in rodents"><entity charOffset="23-32" id="DDI-PubMed.22570363.s7.e0" text="serotonin" /><entity charOffset="114-124" id="DDI-PubMed.22570363.s7.e1" text="citalopram" /><pair ddi="false" e1="DDI-PubMed.22570363.s7.e0" e2="DDI-PubMed.22570363.s7.e0" /><pair ddi="false" e1="DDI-PubMed.22570363.s7.e0" e2="DDI-PubMed.22570363.s7.e1" /></sentence><sentence text=" In healthy human volunteers JNJ-18038683 prolonged REM latency and reduced REM sleep duration, demonstrating that the effect of 5-HT(7) blockade on REM sleep translated from rodents to humans" /><sentence text=" Like in rats, JNJ-18038683 enhanced REM sleep suppression induced by citalopram in humans, although a drug-drug interaction could not be ruled out"><entity charOffset="70-80" id="DDI-PubMed.22570363.s9.e0" text="citalopram" /></sentence><sentence text=" In a double-blind, active, and placebo-controlled clinical trial in 225 patients suffering from major depressive disorder, neither treatment with pharmacologically active doses of JNJ-18038683 or escitalopram separated from placebo, indicating a failed study lacking assay sensitivity" /><sentence text=" Post hoc analyses using an enrichment window strategy, where all the efficacy data from sites with an implausible high placebo response [placebo group Montgomery-Ã…sberg Depression Rating Scale (MADRS) &lt; = 12] and from sites with no placebo response (MADRS &gt; = 28) are removed, there was a clinically meaningful difference between JNJ-18038683 and placebo" /><sentence text=" Further clinical studies are required to characterize the potential antidepressant efficacy of JNJ-18038683" /><sentence text="" /></document>